# Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

> **NCT04056195** · PHASE2 · COMPLETED · sponsor: **Oscotec Inc.** · enrollment: 61 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** SKI-O-703
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04056195
- **Lead sponsor:** Oscotec Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-11
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056195, "Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04056195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*